 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8283848586878889909192...100101» |
- ||||| Ibrance (palbociclib) / Pfizer
Enrollment closed, IO biomarker, Metastases: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - Jul 2, 2017
P3, N=666, Active, not recruiting, Sponsor: Pfizer
Suspended --> Active, not recruiting
- ||| letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jul 2, 2017
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- | metformin / Generic mfg., letrozole / Generic mfg.
Enrollment open: Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Jul 2, 2017
P3, N=80, Recruiting, Sponsor: Assiut University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Trial completion: Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome (clinicaltrials.gov) - Jun 30, 2017
P1, N=25, Completed, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Jun 29, 2017
P1, N=88, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Apr 2019 --> Sep 2018
- | letrozole / Generic mfg.
Trial completion: WISE: Letrozole in Preventing Breast Cancer in Postmenopausal Women (clinicaltrials.gov) - Jun 28, 2017
P2, N=49, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Apr 2019 --> Sep 2018 Recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, PD(L)-1 Biomarker: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Jun 27, 2017
P2, N=22, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed N=18 --> 22
- | letrozole / Generic mfg., zoledronic acid / Generic mfg.
Trial termination, Surgery: FEMZONE: Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer (clinicaltrials.gov) - Jun 26, 2017
P4, N=168, Terminated, Sponsor: Novartis Pharmaceuticals
N=18 --> 22 Completed --> Terminated
- | Ibrance (palbociclib) / Pfizer
Enrollment open, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Jun 26, 2017
P2, N=35, Recruiting, Sponsor: Washington University School of Medicine
Completed --> Terminated Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Enrollment open: Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer (clinicaltrials.gov) - Jun 23, 2017
P=N/A, N=100, Recruiting, Sponsor: Navy General Hospital, Beijing
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- |||| Piqray (alpelisib) / Novartis
Enrollment open, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jun 20, 2017
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date: MONALEESA-2: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Jun 15, 2017
P3, N=668, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2019 --> Jan 2016
- | letrozole / Generic mfg.
Trial primary completion date: T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin (clinicaltrials.gov) - Jun 14, 2017
P1/2, N=56, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Aug 2019 --> Jan 2016 Trial primary completion date: Jun 2017 --> May 2015
- | Menopur (menotropin) / Ferring, Synarel (nafarelin) / Pfizer
Trial completion, Enrollment change, Trial primary completion date: Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization (clinicaltrials.gov) - Jun 9, 2017
P=N/A, N=4, Completed, Sponsor: New Hope Fertility Center
Trial primary completion date: Jun 2017 --> May 2015 Recruiting --> Completed | N=60 --> 4 | Trial primary completion date: Dec 2016 --> Jun 2017
- | letrozole / Generic mfg.
New trial: Letrozole Step-up Protocol for Ovulation Induction in Infertile Women With PCOS (clinicaltrials.gov) - Jun 8, 2017
P=N/A, N=90, Completed, Sponsor: Benha University
- | denifanstat (TVB-2640) / Sagimet Biosci
New P2 trial: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jun 7, 2017
P2, N=80, Not yet recruiting, Sponsor: Mayo Clinic
- || Ibrance (palbociclib) / Pfizer
Trial suspension, IO biomarker, Metastases: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - Jun 2, 2017
P3, N=666, Suspended, Sponsor: Pfizer
Recruiting --> Completed | N=60 --> 4 | Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Suspended
- | capecitabine / Generic mfg.
Trial initiation date, Trial primary completion date, Metastases: MECCA: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (clinicaltrials.gov) - Jun 1, 2017
P3, N=240, Not yet recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Suspended Initiation date: Jun 2016 --> Sep 2017 | Trial primary completion date: May 2019 --> May 2021
- |||||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - May 31, 2017
P3, N=496, Recruiting, Sponsor: Alliance Foundation Trials, LLC.
Initiation date: Jun 2016 --> Sep 2017 | Trial primary completion date: May 2019 --> May 2021 Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Jun 2017
- | Firmagon (degarelix) / Astellas, Ferring
Enrollment closed, Trial primary completion date: TRial on the Endocrine Activity of Neoadjuvant Degarelix (clinicaltrials.gov) - May 31, 2017
P2, N=51, Active, not recruiting, Sponsor: International Breast Cancer Study Group
Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Aug 2017
- | letrozole / Generic mfg.
Journal: Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity. (Pubmed Central) - May 31, 2017
Breast cancer survivors who are prescribed an AI as part of their adjuvant treatment want ongoing communication with their oncology provider about the potential for joint pain side effects and how these symptoms may be managed through regular physical activity. The prescription of an AI presents a "teachable moment" for oncologists to recommend and encourage their patients to engage in regular physical activity.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - May 18, 2017
P2, N=400, Not yet recruiting, Sponsor: MedSIR
- ||| xentuzumab (BI-836845) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - May 18, 2017
P1, N=90, Recruiting, Sponsor: Boehringer Ingelheim
The prescription of an AI presents a "teachable moment" for oncologists to recommend and encourage their patients to engage in regular physical activity. Not yet recruiting --> Recruiting
- | sapanisertib (CB-228) / Calithera
Enrollment open, Trial initiation date, Trial primary completion date: Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer (clinicaltrials.gov) - May 10, 2017
P1b, N=13, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Apr 2017 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||| taselisib (GDC-0032) / Roche
Trial completion, Trial primary completion date: A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) (clinicaltrials.gov) - May 10, 2017
P2, N=330, Completed, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Apr 2017 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Mar 2017
- | letrozole / Generic mfg.
Enrollment closed, Enrollment change, IO biomarker: Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. (clinicaltrials.gov) - May 9, 2017
P=N/A, N=18, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Mar 2017 Recruiting --> Active, not recruiting | N=30 --> 18
- | paclitaxel / Generic mfg.
Trial initiation date: ARETTA: Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer (clinicaltrials.gov) - May 9, 2017
P2, N=60, Not yet recruiting, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | N=30 --> 18 Initiation date: Apr 2017 --> Nov 2017
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Trial initiation date: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib (clinicaltrials.gov) - May 5, 2017
P3, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Apr 2017 --> Nov 2017 Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Nov 2016
- | letrozole / Generic mfg.
Trial primary completion date, BRCA Biomarker: LIBER: Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation (clinicaltrials.gov) - May 4, 2017
P3, N=386, Active, not recruiting, Sponsor: UNICANCER
Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Nov 2016 Trial primary completion date: Feb 2017 --> Feb 2021
- |||| Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - May 3, 2017
P3, N=450, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Feb 2017 --> Feb 2021 Trial primary completion date: Nov 2017 --> Jan 2017
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial primary completion date: NeoPAL: Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women (clinicaltrials.gov) - May 3, 2017
P2, N=125, Active, not recruiting, Sponsor: UNICANCER
Trial primary completion date: Nov 2017 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jan 2018
- | Ibrance (palbociclib) / Pfizer
Phase classification, Metastases: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - May 3, 2017
P2, N=177, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jan 2018 Phase classification: P1/2 --> P2
- || Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 2, 2017
P4, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P1/2 --> P2 Trial primary completion date: Dec 2016 --> Jul 2017
- | letrozole / Generic mfg.
Trial primary completion date: RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF (clinicaltrials.gov) - May 1, 2017
P=N/A, N=50, Recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Dec 2016 --> Jul 2017 Trial primary completion date: Oct 2016 --> Oct 2019
- | metformin / Generic mfg., letrozole / Generic mfg.
New P3 trial: Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Apr 30, 2017
P3, N=80, Not yet recruiting, Sponsor: Assiut University
- ||||| Ibrance (palbociclib) / Pfizer, Aliqopa (copanlisib) / Bayer
New P2 trial, PARP Biomarker: Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (clinicaltrials.gov) - Apr 25, 2017
P2, N=102, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Trial initiation date, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Apr 24, 2017
P1/2, N=40, Not yet recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Oct 2016 --> Oct 2019 Initiation date: Mar 2017 --> Jun 2017
- Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Metastases: Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone (clinicaltrials.gov) - Apr 21, 2017
P2, N=44, Active, not recruiting, Sponsor: Translational Research in Oncology
Initiation date: Mar 2017 --> Jun 2017 Trial primary completion date: Mar 2017 --> Sep 2017
- || Piqray (alpelisib) / Novartis
Trial primary completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Apr 21, 2017
P2, N=160, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Mar 2020 --> Dec 2019
- |||||| Ibrance (palbociclib) / Pfizer
Biomarker, Enrollment open, Combination therapy, Circulating tumor DNA, Metastases: PADA-1: PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (clinicaltrials.gov) - Apr 20, 2017
P3, N=800, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Mar 2020 --> Dec 2019 Not yet recruiting --> Recruiting
- || Kisqali (ribociclib) / Novartis
Enrollment closed, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Apr 19, 2017
P1, N=86, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | letrozole / Generic mfg., zoledronic acid / Generic mfg.
Trial completion: Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer (clinicaltrials.gov) - Apr 18, 2017
P=N/A, N=60, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Ibrance (palbociclib) / Pfizer
Enrollment change, Trial primary completion date, Metastases: INGE-B: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (clinicaltrials.gov) - Apr 13, 2017
P2, N=360, Recruiting, Sponsor: iOMEDICO AG
Active, not recruiting --> Completed N=120 --> 360 | Trial primary completion date: Sep 2021 --> Jun 2019
- Ibrance (palbociclib) / Pfizer
Enrollment closed, Metastases: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Apr 12, 2017
P1, N=25, Active, not recruiting, Sponsor: Pfizer
N=120 --> 360 | Trial primary completion date: Sep 2021 --> Jun 2019 Suspended --> Active, not recruiting
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Apr 7, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Suspended --> Active, not recruiting Trial primary completion date: May 2017 --> Dec 2018
- ||| fexagratinib (ABSK091) / Abbisko
Enrollment closed, Trial primary completion date, Combination therapy: AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) (clinicaltrials.gov) - Apr 7, 2017
P2a, N=56, Active, not recruiting, Sponsor: Imperial College London
Trial primary completion date: May 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Nov 2016
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Apr 6, 2017
P3, N=672, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Apr 4, 2017
P2, N=40, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2018 --> Jul 2019
- | Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: PALEO: Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer (clinicaltrials.gov) - Apr 4, 2017
P2, N=78, Recruiting, Sponsor: Nordic Society for Gynaecologic Oncology
Trial primary completion date: Jul 2018 --> Jul 2019 Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Feb 2017 | Trial primary completion date: Aug 2021 --> Dec 2020
- ||| xentuzumab (BI-836845) / Boehringer Ingelheim
New P1 trial, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - Apr 4, 2017
P1, N=90, Not yet recruiting, Sponsor: Boehringer Ingelheim